SYRE

Spyre Therapeutics (SYRE)

Spyre Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SYRE

1 2 3 4 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/18	06 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SYRE	Spyre Therapeutics Inc
2025/01/18	06 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SYRE	Spyre Therapeutics Inc
2025/01/18	06 : 35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SYRE	Spyre Therapeutics Inc
2025/01/18	06 : 34	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SYRE	Spyre Therapeutics Inc
2025/01/15	07 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SYRE	Spyre Therapeutics Inc
2025/01/13	22 : 08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SYRE	Spyre Therapeutics Inc
2025/01/13	22 : 00	PR Newswire (US)	Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts	NASDAQ:SYRE	Spyre Therapeutics Inc
2025/01/04	07 : 20	PR Newswire (US)	Spyre Therapeutics Announces Grants of Inducement Awards	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/12/18	22 : 00	PR Newswire (US)	Spyre Therapeutics Added to the Nasdaq Biotechnology Index	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/12/03	07 : 03	PR Newswire (US)	Spyre Therapeutics Announces Grants of Inducement Awards	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/12/02	22 : 00	PR Newswire (US)	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/26	07 : 11	PR Newswire (US)	Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/20	07 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/20	06 : 38	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/19	11 : 18	PR Newswire (US)	Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/19	07 : 10	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/19	06 : 14	PR Newswire (US)	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/19	06 : 09	Edgar (US Regulatory)	Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/19	06 : 06	Edgar (US Regulatory)	Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/19	06 : 05	Edgar (US Regulatory)	Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/19	06 : 03	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/19	06 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/15	07 : 50	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/15	06 : 05	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/14	23 : 44	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/12	21 : 30	PR Newswire (US)	Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/12	06 : 05	PR Newswire (US)	Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/09	06 : 53	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/08	06 : 14	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:SYRE	Spyre Therapeutics Inc
2024/11/08	06 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SYRE	Spyre Therapeutics Inc